newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Seeking Alpha
Nurix Therapeutics (NRIX) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche (RHHBY) to develop and commercialize bexobrutideg.
Nurix Therapeutics signed a global collaboration and licensing agreement with Roche on bexobrutideg.
KEY POINTS
The deal is valued at up to $3 billion, with Nurix receiving $700 million upfront.
Bexobrutideg is a potential best-in-class oral BTK degrader for cancer therapy.
Nurix shares surged 43% following the announcement of the Roche collaboration deal.
Nurix surges 43% on up to $3B cancer drug deal with Roche
Comments
Nurix Therapeutics (NRIX) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche (RHHBY) to develop and commercialize bexobrutideg, a potential best-in-class oral BTK degrader, in a deal worth up to $3B, including a $700M upfront
Newsletters for Every Investor
Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters